NextFin News - Adocia SA, the Lyon-based biotechnology firm specializing in metabolic disease treatments, has reported its latest share capital and voting rights figures as of February 28, 2026, revealing a total of 19,607,806 outstanding shares. The regulatory filing, mandated by the French Autorité des Marchés Financiers (AMF), also confirms a total of 21,709,563 theoretical voting rights. This update follows a period of significant capital restructuring for the clinical-stage company, which has been aggressively funding its pipeline in the high-stakes diabetes and obesity markets.
The discrepancy between the number of shares and theoretical voting rights—a difference of over 2.1 million—stems from the French "Loi Florange," which grants double voting rights to shares held in registered form for at least two years. For a biotech firm like Adocia, this structure serves as a critical defensive mechanism, anchoring the company’s governance with long-term shareholders while it navigates the volatile waters of clinical trials and partnership negotiations. As of the end of February, the number of exercisable voting rights stood slightly lower at 21,696,337, accounting for shares held under the company’s liquidity agreement which do not carry voting power.
This snapshot of Adocia’s capital structure arrives just months after the company successfully completed a €10 million fundraising round in December 2025. That capital injection was vital for sustaining the momentum of its proprietary platforms, most notably BioChaperone and the newly patented AdoXLong. The latter, a long-acting peptide platform, represents Adocia’s strategic pivot toward the burgeoning obesity market, where it seeks to compete with or complement the current generation of GLP-1 blockbusters. By maintaining a stable voting structure, management ensures that short-term market fluctuations do not derail these multi-year development cycles.
Financially, Adocia has been operating on a lean but calculated trajectory. Following its Q4 2025 results, the company has focused on extending its cash runway, which was bolstered by milestone payments from its Chinese partner, Tonghua Dongbao. The relationship with Tonghua Dongbao remains a cornerstone of Adocia’s commercial strategy, particularly for its BioChaperone Combo, which targets the massive insulin market in Asia. The current share count reflects a company that has managed to raise capital without catastrophic dilution, a rare feat for European biotechs in the current high-interest-rate environment.
The road ahead for Adocia is inextricably linked to its ability to convert its 25 patent families into late-stage clinical successes. With approximately 80 employees and a market listing on Euronext Paris, the company is small enough to be nimble but large enough to maintain a diverse portfolio. The stability in its voting rights suggests that the founding team and core institutional backers remain in control, providing a predictable governance environment as they approach potential Phase 3 milestones. In the competitive landscape of metabolic health, where giants like Eli Lilly and Novo Nordisk loom large, Adocia’s survival depends on its niche technological advantages in peptide stabilization and oral delivery.
Explore more exclusive insights at nextfin.ai.
